Amylyx Q2 Loss Wider Than Expected, But Avexitide Phase 3 Data Looms
AMLX has more than doubled off its 52-week low of $7.48.
Summary
Amylyx posted a Q2 loss of $0.39 per share, missing the $0.36 consensus, on higher SG&A costs tied to legal expenses and commercial prep. The miss is modest, but the real story is the pipeline: the final patient visit in the pivotal Phase 3 LUCIDITY trial for avexitide is complete, with topline data due in late August or early September. Cash of $250.8M funds operations into 2028, well past the expected 2027 launch if approved. The stock is near its 52-week high, so the market is already pricing in avexitide success — any data disappointment would hit hard. This follows a Q1 report that also showed a wider loss but highlighted Phase 3 enrollment completion.
At the time of this announcement, AMLX was trading at $21.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $7.48 to $22.28. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.